Neuronetics Net Worth

Neuronetics Net Worth Breakdown

  STIM
The net worth of Neuronetics is the difference between its total assets and liabilities. Neuronetics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Neuronetics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Neuronetics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Neuronetics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Neuronetics stock.

Neuronetics Net Worth Analysis

Neuronetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Neuronetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Neuronetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Neuronetics' net worth analysis. One common approach is to calculate Neuronetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Neuronetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Neuronetics' net worth. This approach calculates the present value of Neuronetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Neuronetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Neuronetics' net worth. This involves comparing Neuronetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Neuronetics' net worth relative to its peers.

Enterprise Value

787,356

To determine if Neuronetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuronetics' net worth research are outlined below:
Neuronetics is way too risky over 90 days horizon
Neuronetics has some characteristics of a very speculative penny stock
Neuronetics appears to be risky and price may revert if volatility continues
Neuronetics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 71.35 M. Net Loss for the year was (30.19 M) with profit before overhead, payroll, taxes, and interest of 49.72 M.
Neuronetics currently holds about 73.7 M in cash with (32.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Neuronetics has a poor financial position based on the latest SEC disclosures
Latest headline from gurufocus.com: Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuronetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuronetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Neuronetics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Neuronetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuronetics backward and forwards among themselves. Neuronetics' institutional investor refers to the entity that pools money to purchase Neuronetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-09-30
305.6 K
Hightower Advisors, Llc2024-06-30
158.2 K
Assenagon Asset Management Sa2024-09-30
126 K
State Street Corp2024-06-30
102.1 K
Accurate Wealth Management, Llc2024-09-30
99.2 K
Dorsey & Whitney Trust Co Llc2024-06-30
95.9 K
Gamco Investors, Inc. Et Al2024-09-30
80 K
Gsa Capital Partners Llp2024-09-30
78.6 K
Landscape Capital Management,llc2024-09-30
69.3 K
Archon Capital Management Llc2024-06-30
2.5 M
Kent Lake Capital Llc2024-06-30
1.7 M
Note, although Neuronetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Neuronetics' market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.86 M.

Market Cap

249,354

Project Neuronetics' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.27)(0.28)
Return On Capital Employed(0.32)(0.33)
Return On Assets(0.26)(0.27)
Return On Equity(0.88)(0.93)
The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.52) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.52.
When accessing Neuronetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Neuronetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuronetics' profitability and make more informed investment decisions.

Evaluate Neuronetics' management efficiency

Neuronetics has return on total asset (ROA) of (0.169) % which means that it has lost $0.169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0013) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Neuronetics' Net Tangible Assets are very stable compared to the past year. As of the 26th of November 2024, Other Current Assets is likely to grow to about 7.6 M, while Non Current Assets Total are likely to drop about 13.4 M.
Last ReportedProjected for Next Year
Book Value Per Share 1.19  1.25 
Tangible Book Value Per Share 1.05  1.10 
Enterprise Value Over EBITDA(3.77)(3.96)
Price Book Value Ratio 2.43  1.94 
Enterprise Value Multiple(3.77)(3.96)
Price Fair Value 2.43  1.94 
Enterprise Value828.8 K787.4 K
The operational strategies employed by Neuronetics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue
0.7443
Revenue
72.1 M
Quarterly Revenue Growth
(0.07)
Revenue Per Share
2.453
Return On Equity
(1.00)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuronetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuronetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuronetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Conley Sheryl L over two weeks ago
Acquisition by Conley Sheryl L of 25000 shares of Neuronetics subject to Rule 16b-3
 
Muir Glenn P over a month ago
Acquisition by Muir Glenn P of 25000 shares of Neuronetics at 1.0 subject to Rule 16b-3
 
Macan William Andrew over a month ago
Disposition of 1541 shares by Macan William Andrew of Neuronetics at 0.82 subject to Rule 16b-3
 
Cascella Robert over two months ago
Acquisition by Cascella Robert of 100000 shares of Neuronetics at 0.75 subject to Rule 16b-3
 
Muir Glenn P over two months ago
Acquisition by Muir Glenn P of 25000 shares of Neuronetics at 0.8 subject to Rule 16b-3
 
Muir Glenn P over two months ago
Acquisition by Muir Glenn P of 12224 shares of Neuronetics at 0.85 subject to Rule 16b-3
 
Muir Glenn P over two months ago
Acquisition by Muir Glenn P of 12776 shares of Neuronetics at 0.85 subject to Rule 16b-3
 
Cascella Robert over three months ago
Acquisition by Cascella Robert of 4000 shares of Neuronetics at 1.14 subject to Rule 16b-3
 
Cascella Robert over three months ago
Acquisition by Cascella Robert of 35000 shares of Neuronetics at 1.06 subject to Rule 16b-3
 
Keith Sullivan over three months ago
Disposition of 11687 shares by Keith Sullivan of Neuronetics at 1.97 subject to Rule 16b-3
 
Keith Sullivan over three months ago
Disposition of 12075 shares by Keith Sullivan of Neuronetics at 1.91 subject to Rule 16b-3
 
Furlong Stephen over three months ago
Disposition of 5813 shares by Furlong Stephen of Neuronetics at 3. subject to Rule 16b-3
Neuronetics time-series forecasting models is one of many Neuronetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neuronetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Neuronetics Earnings per Share Projection vs Actual

Neuronetics Corporate Management

When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.22)
Revenue Per Share
2.453
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.17)
Return On Equity
(1.00)
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.